Clinicopathological Reclassification of Idiopathic Inflammatory Myopathy to Match the Serological Results of Myositis-Specific Antibodies
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Advances in serological tests are transforming the classification of idiopathic inflammatory myopathy (IIM). The new criteria suggested by the 119th European Neuromuscular Center international workshop divide IIM cases into four main diseases according to clinical and pathological findings, adding immune-mediated necrotizing myositis and nonspecific myositis to the classic categories of polymyositis and dermatomyositis. Methods Seventy one cases of IIM with sufficient available clinical and pathological data were reviewed to be reclassified according to the new criteria. Results Most of the cases previously classified as polymyositis (77.8%, 35/45) were reclassified as immune-mediated necrotizing myopathy. The results of myositis-specific antibodies matched well with the new clinicopathological classification. Conclusions This new clinicopathological classification for IIM in combination with serological test results could be applied to our previous case series. Adoption of the new criteria will lead to a better understanding of the disease and hence new therapeutic insights.
Abstract
Background and Purpose Advances in serological tests are transforming the classification of idiopathic inflammatory myopathy (IIM). The new criteria suggested by the 119th European Neuromuscular Center international workshop divide IIM cases into four main diseases according to clinical and pathological findings, adding immune-mediated necrotizing myositis and nonspecific myositis to the classic categories of polymyositis and dermatomyositis. Methods Seventy one cases of IIM with sufficient available clinical and pathological data were reviewed to be reclassified according to the new criteria. Results Most of the cases previously classified as polymyositis (77.8%, 35/45) were reclassified as immune-mediated necrotizing myopathy. The results of myositis-specific antibodies matched well with the new clinicopathological classification. Conclusions This new clinicopathological classification for IIM in combination with serological test results could be applied to our previous case series. Adoption of the new criteria will lead to a better understanding of the disease and hence new therapeutic insights.
참고문헌 (14)
- Bohan A, "Polymyositis and dermatomyositis(first of two parts)", N Engl J Med, 292, pp.344~347 (1975)
- Bohan A, "Polymyositis and dermatomyositis(second of two parts)", N Engl J Med, 292, pp.403~407 (1975)
- Selva-O’Callaghan A, "Classification and management of adult inflammatory myopathies", Lancet Neurol, 17, pp.816~828 (2018)
- Hoogendijk JE, "119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands", Neuromuscul Disord, 14, pp.337~345 (2004)
- De Bleecker JL, "193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November-2December 2012, Naarden, the Netherlands", Neuromuscul Disord, 23, pp.945~951 (2013)
- De Bleecker JL, "205th ENMC international workshop : pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, the Netherlands", Neuromuscul Disord, 25, pp.268~272 (2015)
- Ghirardello A, "New insights in myositis-specific autoantibodies", Curr Opin Rheumatol, 30, pp.614~622 (2018)
- Fredi M, "The clinico-serological spectrum of overlap myositis", Curr Opin Rheumatol, 30, pp.637~643 (2018)
- Tanboon J, "Classification of idiopathic inflammatory myopathies : pathology perspectives", Curr Opin Neurol, 32, pp.704~714 (2019)
- Dalakas MC, "Polymyositis and dermatomyositis", Lancet, 362, pp.971~982 (2003)
- van der Meulen MF, "Polymyositis : an overdiagnosed entity", Neurology, 61, pp.316~321 (2003)
- Amato AA, "Unicorns, dragons, polymyositis, and other mythological beasts", Neurology, 61, pp.288~289 (2003)
- Pinal-Fernandez I, "Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle", Arthritis Care Res(Hoboken), 69, pp.263~270 (2017)
- Uruha A, "Sarcoplasmic MxA expression : a valuable marker of dermatomyositis", Neurology, 88, pp.493~500 (2017)